Article Versions Notes

Tatineni V, O’Shea PJ, Ozair A, Khosla AA, Saxena S, Rauf Y, Jia X, Murphy ES, Chao ST, Suh JH, et al. First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases. Cancers. 2023; 15(8):2382. https://doi.org/10.3390/cancers15082382

Tatineni, Vineeth, Patrick J. O’Shea, Ahmad Ozair, Atulya A. Khosla, Shreya Saxena, Yasmeen Rauf, Xuefei Jia, Erin S. Murphy, Samuel T. Chao, John H. Suh, and et al. 2023. "First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases" Cancers 15, no. 8: 2382. https://doi.org/10.3390/cancers15082382

Tatineni, V., O’Shea, P. J., Ozair, A., Khosla, A. A., Saxena, S., Rauf, Y., Jia, X., Murphy, E. S., Chao, S. T., Suh, J. H., Peereboom, D. M., & Ahluwalia, M. S. (2023). First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases. Cancers, 15(8), 2382. https://doi.org/10.3390/cancers15082382